Russian shot in the arm

"The value of the investment amounts to $20 [zł.68] million. It will be financed jointly with our two Russian partners," said Adam Wilczęga, president of Bioton. In Q4, Bioton will sell its insulin on the Russian market and also deliver products to Belarus and Ukraine.